Compare Bristol-Myers Squibb Co (BMY) vs Indonesia Energy Corporation Limited (INDO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bristol-Myers Squibb Co vs Indonesia Energy Corporation Limited — how do they compare? Bristol-Myers Squibb Co trades at $56.99 (market cap $116.30B), while Indonesia Energy Corporation Limited trades at $2.94 (market cap $45.24M). The key difference: Bristol-Myers Squibb Co is far larger — about 2570.7× Indonesia Energy Corporation Limited's market cap, and Bristol-Myers Squibb Co pays a 4.42% dividend while Indonesia Energy Corporation Limited pays none. Which is the better fit depends on your goals.
| BMY | INDO | |
|---|---|---|
Market Cap | $116.30B | $45.24M |
Sector | Health | Energy |
52-Week High | $62.37 | $6.74 |
52-Week Low | $42.60 | $2.49 |
Enterprise Value | $152.24B | $40.61M |
Dividend Yield | 4.42% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bristol Myers Squibb (BMY) trades at $59.34, up 3.06% today, with a bullish technical signal and consistent earnings beats. The stock shows strong profitability with a 15.01% net margin and 38.84% ROE, though debt levels have risen. Recent FDA acceptance for mezigdomide in multiple myeloma highlights pipeline progress. Analysts are mixed with a $60 consensus target, slightly above current price.
BMY offers value with a P/E of 16.62 and a safe 4.3% dividend yield, but faces patent cliff risks and pricing pressures. Earnings growth and pipeline execution are key catalysts, while high debt and competitive threats require monitoring. The stock presents a balanced opportunity for income-focused investors with moderate risk tolerance.
INDO trades at $3.00, up 9.49% today, with a bullish technical signal from moving averages and oscillators. The company reported a net loss of $5 million on $2 million revenue in 2025, with negative profit margins. Recent news highlights operational progress, including the commencement of drilling at the Kruh Block. Analyst consensus is unanimously bullish with 3 buy ratings.
The outlook hinges on successful execution of new well operations to drive revenue growth and reduce losses. Key risks include sustained negative profitability and operational challenges in oil exploration. Upside potential exists if production targets are met, but investors face significant financial and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bristol-Myers Squibb Co
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Unlike some of its more diversified peers, Bristol has exited several nonpharmaceutical businesses to focus on branded specialty drugs, which tend to support strong pricing power.
Read more on BMY →About Indonesia Energy Corporation Limited
Indonesia Energy is an oil and gas exploration and production company. It focuses on identifying and developing energy resources in Indonesia, primarily through its Kruh and Citarum blocks.
Read more on INDO →
